Description
Anti-RSV Antibody, Non-Fucosylated (BioBet-028ZP) is a human monoclonal IgG antibody against RSV. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Infections, Respiratory Syncytial Virus
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced RSV antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
cytotoxic T-lymphocyte associated protein 4
Background
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
Alternative Names
CD; GSE; GRD4; ALPS5; CD152; RSV; IDDM12; CELIAC3
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CTLA4 include Autoimmune Lymphoproliferative Syndrome, Type V and Celiac Disease 3.
Related Pathways
Its related pathways are TCR Signaling (Qiagen) and T cell receptor signaling pathway.
Function
Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Post-translational modifications
1.N-glycosylation is important for dimerization. 2.Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-028ZP
Species Reactivity
Respiratory Syncytial Virus
Description
Palivizumab is a humanized monoclonal antibody (IgG) that targets the epitope of the RSV F protein A antigenic site. It is used to prevent respiratory syncytial virus (RSV) infection. Palizumab was approved for medical use in 1998.
Antibody Indication
Infections, Respiratory Syncytial Virus
